NYSE announced on March 2 2026 that it will begin formal delisting proceedings against Allurion Technologies Inc. (ALUR) because the company has not met the exchange’s continued‑listing standards. Trading in ALUR’s common stock and warrants will remain on the NYSE until the Exchange’s Committee reviews the company’s status.
The delisting action is triggered by Allurion’s failure to maintain either $50 million in stockholders’ equity or $50 million in market capitalization on a 30‑day average basis, as required by Section 802.01B of the Listed Company Manual. The company’s most recent filings show stockholders’ equity of $4.2 million and a market capitalization of $12 million, far below the thresholds.
Allurion previously received a notice of non‑compliance on August 29 2024 for the same standards and a separate notice on August 15 2024 for a share price below $1.00. The company has indicated it will appeal the current determination and expects its shares to continue trading while the appeal is pending.
Management has highlighted the U.S. FDA approval of the Allurion Gastric Balloon System on February 23 2026 as a key catalyst for regaining compliance. CEO Dr. Shantanu Gaur said the approval “will catalyze the remaining parts of our plan to regain compliance or relist, and we expect our common stock to remain trading on the NYSE while we execute this plan.”
Allurion’s financial health remains strained. As of September 30 2025, cash and cash equivalents were $6.1 million against total debt of $83 million. Operating margin was –156.3 % in the last reported period, and revenue declined 39.9 % year‑over‑year. The company is pursuing capital‑raising efforts, debt restructuring by exchanging debt for preferred stock, and a warrant inducement transaction to improve liquidity and equity.
The delisting risk could reduce liquidity, limit access to capital markets, and accelerate the company’s financial challenges. If removed from the NYSE, Allurion would need to seek alternative listings or private financing, potentially at higher cost and with less visibility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.